Investigation of Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Multiple Doses of Somapacitan in Subjects With Various Degrees of Impaired Renal Function Compared to Subjects With Normal Renal Function
Phase of Trial: Phase I
Latest Information Update: 08 Nov 2017
At a glance
- Drugs Somapacitan (Primary)
- Indications Somatotropin deficiency
- Focus Pharmacokinetics
- Sponsors Novo Nordisk
- 22 Jun 2017 Planned End Date changed from 15 May 2018 to 16 May 2018.
- 22 Jun 2017 Status changed from not yet recruiting to recruiting.
- 16 Jun 2017 New trial record